Zacks Investment Research downgraded Nantkwest Inc (NASDAQ:NK) to Hold in a report released today.
- Updated: September 17, 2016
Zacks Investment Research has downgraded Nantkwest Inc(NASDAQ:NK) to Hold in a statement released on 8/18/2016.
Yesterday Nantkwest Inc (NASDAQ:NK) traded 3.71% higher at $7.87. Nantkwest Inc’s 50-day average is $7.68 and its two hundred day average is $7.66. With the last stock close up 20.52% from the two hundred day average, compared with the S&P 500 which has fallen -0.01% over the same time. 839,549 shares of the stock traded, up from ann avg. volume of 266,048.
Recent Performance Graph:
Nantkwest Inc has a one-year low of $5.43 and a 52 week high of $19.87. The company’s market cap is currently $0.0.
In addition to Zacks Investment Research reporting it’s stock price target, a total of 6 brokerages have reported on Nantkwest Inc. The one year target stock price is $26.17 with 0 rating the company a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 analystsrating the company as sell.
Brief Synopsis On Nantkwest Inc (NASDAQ:NK)
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, and non-hodgkin lymphoma and myelodysplastic syndrome.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.